(Q44878564)

English

Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes

scientific article published in November 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

based on heuristic

inferred from title

author name string

M L Shiffman

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

S B Verbeke

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

P M Kimball

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

publication date

1 November 2000

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Antiviral Research

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

91-99

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The mechanisms of chronicity in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferons in host defense

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in cell cycling and apoptosis contribute to reduced effector cell generation among long-term heart transplant survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitivity of intracellular signals responsible for cell cycle progression to cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The paradox of cytokine monitoring-predictor of immunologic activity as well as immunologic silence following cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokines in viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential sensitivity of hepatitis C virus quasispecies to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferons: biological and clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferons and their actions

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of action of interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Ribavirin on Neutrophil Function

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900120-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0166-3542(00)00120-0

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44878564&oldid=2055056978"